Australia’s Therapeutic Goods Administration says the levels of potential carcinogen N-nitrosodimethylamine (NDMA) its testing has identified in ranitidine heartburn remedies are “unacceptable” leading the agency to withdraw numerous products from sale.
Prompted by US Food and Drug Administration and European Medicines Agency warnings about potential ranitidine contamination in September, the TGA tested 135 batch samples of ranitidine drugs (from 34 products) sold in Australia by 10 different sponsors
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?